Drug transporter expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line

Januchowski, Radosław; Zawierucha, Piotr; Ruciński, Marcin; Andrzejewska, Małgorzata; Wójtowicz, Karolina; Nowicki, Michał; Zabel, Maciej

doi:10.1016/j.biopha.2014.02.002

Cited by 66 publications

(50 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In ovarian cancer, ABCA8 is significantly (>10-fold) increased in drug-resistant A2780 cells (55), consistent with the results in this study (Fig. 5).…”

Section: Discussionsupporting

confidence: 92%

Discovery of microarray-identified genes associated with ovarian cancer progression

Liu

Gao

Zhao

et al. 2015

International Journal of Oncology

View full text Add to dashboard Cite

“…In ovarian cancer, ABCA8 is significantly (>10-fold) increased in drug-resistant A2780 cells (55), consistent with the results in this study (Fig. 5).…”

Section: Discussionsupporting

confidence: 92%

Discovery of microarray-identified genes associated with ovarian cancer progression

Liu

Gao

Zhao

et al. 2015

International Journal of Oncology

View full text Add to dashboard Cite

“…Expression of BCRP has been reported by others in ovarian cancer cell lines exposed to TOP (13,17) as well as in many drug-resistant solid tumors and was associated with mitoxantrone, topotecan, irinotecan, flavopiridol and methotrexate resistance (14,17). Previously we also observed an increased expression of ABCG2 gene in TOP-resistant variants of A2780 (15,16) and W1 cell lines (18,39). These results indicate that increased expression of BCRP transporter is the main mechanism of TOP resistance in ovarian cancer.…”

Section: Discussionsupporting

confidence: 79%

“…The main protein responsible for active removal of TOP from cancer cells is BCRP (breast cancer resistant protein) encoded by ABCG2 gene. Expression of this gene was reported among others in breast and ovarian cancer and cancer cell lines (13)(14)(15)(16)(17). In our previous study we observed that TOP resistance could be also related to expression of glycoprotein P (P-gp) encoded by ABCB1 (MDR1) gene (16,18).…”

Section: Abstract Background: Low Effectiveness Of Chemotherapy In Omentioning

confidence: 80%

New and Old Genes Associated with Topotecan Resistance Development in Ovarian Cancer Cell Lines

2017

View full text Add to dashboard Cite

“…OAT is positively regulated by β-catenin and cAMP and inhibition of OAT in HCC suppresses proliferation505152. SLC16A14 is a poorly characterized monocarboxylate transporter suggested to play a role in resistance to chemotherapy in ovarian cancer53.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma

Dinh

Vitucci

Wauthier

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Fibrolamellar carcinoma (FLC) is a unique liver cancer primarily affecting young adults and characterized by a fusion event between DNAJB1 and PRKACA. By analyzing RNA-sequencing data from The Cancer Genome Atlas (TCGA) for >9,100 tumors across ~30 cancer types, we show that the DNAJB1-PRKACA fusion is specific to FLCs. We demonstrate that FLC tumors (n = 6) exhibit distinct messenger RNA (mRNA) and long intergenic non-coding RNA (lincRNA) profiles compared to hepatocellular carcinoma (n = 263) and cholangiocarcinoma (n = 36), the two most common liver cancers. We also identify a set of mRNAs (n = 16) and lincRNAs (n = 4), including LINC00473, that distinguish FLC from ~25 other liver and non-liver cancer types. We confirm this unique FLC signature by analysis of two independent FLC cohorts (n = 20 and 34). Lastly, we validate the overexpression of one specific gene in the FLC signature, carbonic anhydrase XII (CA12), at the protein level by western blot and immunohistochemistry. Both the mRNA and lincRNA signatures support a major role for protein kinase A (PKA) signaling in shaping the FLC gene expression landscape, and present novel candidate FLC oncogenes that merit further investigation.

show abstract

Drug transporter expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line

Cited by 66 publications

References 32 publications

Discovery of microarray-identified genes associated with ovarian cancer progression

Discovery of microarray-identified genes associated with ovarian cancer progression

New and Old Genes Associated with Topotecan Resistance Development in Ovarian Cancer Cell Lines

Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma

Contact Info

Product

Resources

About